Effects of discontinuing oral bisphosphonate treatments for postmenopausal osteoporosis on bone turnover markers and bone density

The effect of bisphosphonate treatment on osteoclast precursor cells in postmenopausal osteoporosis: The TRIO study

(2016) F. Gossiel et al.   BONE

Managing Osteoporosis in Patients on Long-Term Bisphosphonate Treatment: Report of a Task Force of the American Society for Bone and Mineral Research

(2016) Robert A Adler et al.   JOURNAL OF BONE AND MINERAL RESEARCH

Bisphosphonate therapy: how long is long enough?

(2015) M. R. McClung   OSTEOPOROSIS INTERNATIONAL

Response of bone turnover markers to three oral bisphosphonate therapies in postmenopausal osteoporosis: the TRIO study

(2015) K. E. Naylor et al.   OSTEOPOROSIS INTERNATIONAL

The Incidence of Osteonecrosis of the Jaw in Patients Receiving 5 Milligrams of Zoledronic Acid

(2014) John T. Grbic et al.   JOURNAL OF THE AMERICAN DENTAL ASSOCIATION

Comparison of the effects of three oral bisphosphonate therapies on the peripheral skeleton in postmenopausal osteoporosis: the TRIO study

(2014) M. A. Paggiosi et al.   OSTEOPOROSIS INTERNATIONAL

Fracture Prediction After Discontinuation of 4 to 5 Years of Alendronate Therapy

(2014) Douglas C. Bauer et al.   JAMA Internal Medicine

IDS iSYS automated intact procollagen-1-N-terminus pro-peptide assay: method evaluation and reference intervals in adults and children

(2013) Alireza Morovat et al.   CLINICAL CHEMISTRY AND LABORATORY MEDICINE

BMD changes and predictors of increased bone loss in postmenopausal women after a 5-year course of alendronate

(2013) Brian Louis McNabb et al.   JOURNAL OF BONE AND MINERAL RESEARCH

Diagnosis and management of osteoporosis in postmenopausal women and older men in the UK: National Osteoporosis Guideline Group (NOGG) update 2013

(2013) J. Compston et al.   MATURITAS

Bisphosphonate drug holiday: who, when and how long

(2013) Dima L. Diab et al.   Therapeutic Advances in Musculoskeletal Disease

Bisphosphonate Therapy for Osteoporosis: Benefits, Risks, and Drug Holiday

(2012) Michael McClung et al.   AMERICAN JOURNAL OF MEDICINE

Bisphosphonates for Osteoporosis — Where Do We Go from Here?

(2012) Marcea Whitaker et al.   NEW ENGLAND JOURNAL OF MEDICINE

Prolonged bisphosphonate release after treatment in women with osteoporosis. Relationship with bone turnover

(2011) P. Peris et al.   BONE

The effect of 3 versus 6 years of Zoledronic acid treatment of osteoporosis: A randomized extension to the HORIZON-Pivotal Fracture Trial (PFT)

(2011) Dennis M Black et al.   JOURNAL OF BONE AND MINERAL RESEARCH

Effect of Stopping Risedronate after Long-Term Treatment on Bone Turnover

(2011) Richard Eastell et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Effects of Denosumab Treatment and Discontinuation on Bone Mineral Density and Bone Turnover Markers in Postmenopausal Women with Low Bone Mass

(2011) Henry G. Bone et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Regional bone metabolism at the lumbar spine and hip following discontinuation of alendronate and risedronate treatment in postmenopausal women

(2011) M. L. Frost et al.   OSTEOPOROSIS INTERNATIONAL

Denosumab and bisphosphonates: Different mechanisms of action and effects

(2010) Roland Baron et al.   BONE

Long-Term Use of Bisphosphonates in Osteoporosis

(2010) Nelson B. Watts et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Bisphosphonates and Fractures of the Subtrochanteric or Diaphyseal Femur

(2010) Dennis M. Black et al.   NEW ENGLAND JOURNAL OF MEDICINE

Denosumab for Prevention of Fractures in Postmenopausal Women with Osteoporosis

(2009) Steven R. Cummings et al.   NEW ENGLAND JOURNAL OF MEDICINE

Alendronate reduces osteoclast precursors in osteoporosis

(2009) P. D’Amelio et al.   OSTEOPOROSIS INTERNATIONAL

Effect of denosumab on bone density and turnover in postmenopausal women with low bone mass after long-term continued, discontinued, and restarting of therapy: A randomized blinded phase 2 clinical trial

(2008) Paul D. Miller et al.   BONE

Mechanisms of action of bisphosphonates: similarities and differences and their potential influence on clinical efficacy

(2008) R. G. G. Russell et al.   OSTEOPOROSIS INTERNATIONAL